We generated mice that overexpress protein targeting to glycogen (PTG) in the liver (PTGOE), which results in an increase in liverglycogen. When fed a high-fat diet (HFD), these animals reduced their foodintake. The resulting effect was a lower body weight, decreased fat mass and reduced leptin levels. Furthermore, PTG overexpression reversed the glucose intolerance and hyperinsulinemia caused by the HFD and protected against HFD-induced hepatic steatosis. Remarkably, when fed a HFD, PTGOE mice did not show the decrease in hepatic ATP content observed in control animals and had lower expression of neuropeptide Y (NPY) and higher expression of propiomelanocortin (POMC) in the hypothalamus. Additionally, after an overnight fast, PTGOE animals presented high liverglycogen content, lower liver triacylglycerol content, and lower serum concentrations of fatty acids and β-hydroxybutyrate compared to control mice, regardless whether they received a HFD or a standard diet (SD). In conclusion, liverglycogen accumulation caused a reduced foodintake, protected against the deleterious effects of a HFD and diminished the metabolic impact of fasting.
Therefore, we propose that hepatic glycogen content be considered a potential target for the pharmacological manipulation of diabetes and obesity.
Medical opinion and guidance should always be sought for any symptoms that might possibly reflect a known or suspected disease, disorder or medical condition. Information provided on this website (or by FAB Research via any other means) does not in any way constitute advice on the treatment of any medical condition formally diagnosed or otherwise.